Scarica l'app Stockscreener
41.62
2.67%
-1.14
Dopo l'orario di chiusura:
41.62
Precedente Chiudi:
$42.76
Aprire:
$42.89
Volume 24 ore:
718.33K
Relative Volume:
0.85
Capitalizzazione di mercato:
$3.22B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-15.19
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
+3.05%
1M Prestazione:
+0.95%
6M Prestazione:
+15.64%
1 anno Prestazione:
+5.37%
Intervallo 1D:
$41.50
$43.00
Intervallo di 1 settimana:
$40.74
$43.66
Portata 52W:
$26.74
$46.60
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
41.62 | 3.30B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharma To Report Epilepsy Trial Results Next Month - RTTNews
Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Strong Buy Ratings and 31.57% Potential Upside - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (XENE) Movement - Stock Traders Daily
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - Defense World
Published on: 2026-02-04 12:37:47 - baoquankhu1.vn
Xenon Pharmaceuticals (XENE) Stock Analysis: A Biotech Gem with 33.91% Upside Potential - DirectorsTalk Interviews
Published on: 2026-02-02 18:11:01 - baoquankhu1.vn
Published on: 2026-01-30 01:17:54 - mfd.ru
J. Safra Sarasin Holding AG Sells 51,880 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Market Catalysts: Is Xenon Pharmaceuticals Inc forming a bullish divergence2025 Winners & Losers & Technical Pattern Alert System - baoquankhu1.vn
Rate Hike: What is the Moat Score of WETHWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Action: Does Xenon Pharmaceuticals Inc stock have upside surprise potentialWeekly Loss Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Xenon (XENE) Receives a Buy from J.P. Morgan - The Globe and Mail
Published on: 2026-01-20 17:07:34 - baoquankhu1.vn
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: A 38.87% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Campbell & CO Investment Adviser LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ten new Xenon hires receive 42,300 stock options vesting over 4 years - Stock Titan
Behavioral Patterns of XENE and Institutional Flows - Stock Traders Daily
Trend Recap: Is Xenon Pharmaceuticals Inc stock undervalued right nowJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Xenon Pharmaceuticals (XENE) Stock Analysis: Biotechnology Innovator with a 34% Upside Potential - DirectorsTalk Interviews
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals CEO sells shares worth $2.21 million - MSN
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference - The Globe and Mail
New seizure and depression drug faces key 2026 test in late-stage trials - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $62.00 at JPMorgan Chase & Co. - Defense World
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE) - The Globe and Mail
JPMorgan Chase & Co. Increases Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $62.00 - MarketBeat
JPMorgan reiterates Overweight rating on Xenon Pharmaceuticals stock By Investing.com - Investing.com UK
XENE: JP Morgan Raises Xenon Pharmaceuticals' Price Target | XEN - GuruFocus
Can Xenon Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Institutional & Daily Risk Controlled Trade Plans - Улправда
Is Xenon Pharmaceuticals Inc. stock supported by strong cash flowsMarket Sentiment Summary & Smart Allocation Stock Reports - Улправда
Can Xenon Pharmaceuticals Inc. stock maintain operating marginsQuarterly Trade Review & Stepwise Trade Execution Plans - Улправда
How rising interest rates impact Xenon Pharmaceuticals Inc. stockLong-Term Growth Stocks & We Spotted the Next Tesla – See Inside - Улправда
Why Xenon Pharmaceuticals Inc. stock remains undervaluedForecast Cut & Free Reliable Trade Execution Plans - ulpravda.ru
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears - TechStock²
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighTime to Buy? - MarketBeat
Xenon to Showcase Neuroscience Pipeline at J.P. Morgan Healthcare Conference - TipRanks
Cantor Fitzgerald raises Xenon Pharmaceuticals stock price target to $55 By Investing.com - Investing.com UK
Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
(XENE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy? - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% HigherHere's Why - MarketBeat
Analysts Conflicted on These Healthcare Names: Lifecore Biomedical (LFCR) and Xenon (XENE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options - Nasdaq
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xenon Pharmaceuticals Inc Azioni (XENE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Jan 02 '26 |
Sale |
44.43 |
40,000 |
1,777,093 |
6,000 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):